Spirapril (Renormax) is an ACE inhibitor antihypertensive drug used to treat hypertension. Spiraprilat, the active metabolite of spirapril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Spiraprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.

Mebrofenin is a chelating component which, when attached to Technetium TC-99M, forms a diagnostic drug marketed under the name Choletec. Choletec is approved by FDA as a hepatobiliary imaging agent.

Halquinols (halquinol) is an antimicrobial for treatment of skin infections available as topical skin pharmaceutical. Tarquinor skin cream, a dermatological preparation of halquinol 0.2% and 1% coal tar has been approved for use in New Zealand in 1962 and is in use in Australia at present. Halquinols has a broad antimicrobial activity in vitro against a wide variety of bacteria, fungi and protozoa including Candida albicans, Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis and Streptococcus pyogenes. It has a significant antimycoplasmal (MICs of 3 to 4 ug/ml) and anticryptosporidial activity at 1 or 20 uM against Cryptosporidium parvum. As some antimicrobials halquinol has been used as a growth promotor in poultry. Study of fresh water fish Catla catla treated with halquinol suggested enhanced anabolic metabolism resulting in weight gain. However, the mechanisms by which the drug improves performance are not fully understood. Halquinol was the only antimicrobial drug tested in chicken that did not affect microbial membership compared to the control group.

Spirapril (Renormax) is an ACE inhibitor antihypertensive drug used to treat hypertension. Spiraprilat, the active metabolite of spirapril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Spiraprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.

Spirapril (Renormax) is an ACE inhibitor antihypertensive drug used to treat hypertension. Spiraprilat, the active metabolite of spirapril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Spiraprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.

Spirapril (Renormax) is an ACE inhibitor antihypertensive drug used to treat hypertension. Spiraprilat, the active metabolite of spirapril, competes with angiotensin I for binding at the angiotensin-converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Inhibition of ACE results in decreased plasma angiotensin II. As angiotensin II is a vasoconstrictor and a negative-feedback mediator for renin activity, lower concentrations result in a decrease in blood pressure and stimulation of baroreceptor reflex mechanisms, which leads to decreased vasopressor activity and to decreased aldosterone secretion. Spiraprilat may also act on kininase II, an enzyme identical to ACE that degrades the vasodilator bradykinin.

Mebrofenin is a chelating component which, when attached to Technetium TC-99M, forms a diagnostic drug marketed under the name Choletec. Choletec is approved by FDA as a hepatobiliary imaging agent.